Riabni (rituximab or rituximab-arrx) is an anti-CD20 monoclonal antibody. It’s used to treat certain blood cancers (e.g., chronic lymphocytic leukemia) and autoimmune conditions (e.g., rheumatoid arthritis). Ruxience (rituximab) is given as an infusion through the vein (IV), usually at an infusion center. This is so your care team can monitor and treat you for any serious infusion-related reactions, such as trouble breathing and swelling. Other possible side effects of this medication include rash and infection. Ruxience (rituximab) is a biosimilar to Rituxan (rituximab), but it’s not yet FDA-approved to treat all conditions Rituxan (rituximab) is approved for.
Blood cancers
Certain types of CD20-positive non-Hodgkin’s lymphoma (NHL) in adults
CD20-positive chronic lymphocytic leukemia (CLL) in adults
Autoimmune conditions
Moderate to severe rheumatoid arthritis (RA) in adults
Granulomatosis with polyangitis (GPA) and microscopic polyangitis (MPA) in adults
Ruxience (rituximab) is an anti-CD20 monoclonal antibody. It targets specific cells in your immune system called B cells. B cells are involved in many different health conditions. For example, sometimes they can turn into cancer cells, and other times they become too active, which can cause autoimmune conditions.
Ruxience (rituximab) works by attaching to a specific protein in B cells called CD20. When it attaches to this protein, it signals the body to attack and kill that cell. As a result, these abnormal or overactive B cells can’t grow, spread, or work as well.
Source: DailyMed
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur:
More common
Black, tarry stools
bleeding gums
bloating or swelling of the face, arms, hands, lower legs, or feet
blood in the urine or stools
blurred vision
body aches or pain
burning or stinging of the skin
chills
confusion
difficulty with breathing
dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
drowsiness
ear congestion
flushed, dry skin
fruit-like breath odor
headache
increased hunger
increased thirst
increased urination
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
lower back or side pain
nervousness
noisy breathing
pain or tenderness around the eyes and cheekbones
painful cold sores or blisters on the lips, nose, eyes, or genitals
painful or difficult urination
pale skin
pinpoint red spots on the skin
pounding in the ears
seizures
slow or fast heartbeat
sores, ulcers, or white spots in the mouth or on the lips
stomach pain
stuffy or runny nose
sweating
swelling of the tongue or throat
swollen glands
tightness of the chest
tingling of the hands or feet
troubled breathing with exertion
unusual bleeding or bruising
unusual tiredness or weakness
unusual weight gain or loss
vomiting
Less common
Blistering, peeling, or loosening of the skin
blisters on the trunk, scalp, or other areas
burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feeling
decreased frequency and amount of urine
difficulty with moving
discouragement
feeling sad or empty
irregular heartbeat
irritability
joint or muscle pain
loss of appetite
loss of interest or pleasure
lump or growth on the skin
muscle cramp, pain, or stiffness
numbness or tingling in the hands, feet, or lips
painful blisters on the trunk of the body
pain or redness at the injection site
pain, swelling, or redness in the joints
pounding or irregular heartbeat or pulse
red skin lesions, often with a purple center
red, itchy lining of the eye
redness of the face, neck, arms, and occasionally, upper chest
stabbing pain
trouble concentrating
trouble sleeping
Incidence not known
Blue-yellow color blindness
blurred vision or other change in vision
burning or stinging of the skin
decreased vision
dilated neck veins
extreme tiredness or weakness
eye pain, tearing
feeling of discomfort, illness, or weakness
irregular breathing
nosebleed
painful cold sores or blisters on the lips, nose, eyes, or genitals
sensitivity of the eye to light
severe abdominal or stomach pain
severe vomiting, sometimes with blood
sores, welts, or blisters
stomach cramps
swelling, stiffness, redness, or warmth around many joints
swollen lymph glands
vision loss
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
Agitation or anxiety
bone pain
burning, dry, or itching eyes
change in taste
discharge, excessive tearing
excessive muscle tone
feeling of constant movement of self or surroundings
increase in body movements
lightheadedness
muscle tension
redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
sensation of spinning
sleepiness
swelling of the stomach
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Works in a more targeted, specific way than chemotherapy
Might only need a dose once every 6 months for certain conditions
Doesn’t typically cause hair loss
Each infusion can last over 3 hours, so can be inconvenient
Might cause infusion reactions
Higher risk of infections can last a year after your last dose (sometimes longer)
How often you need a Ruxience (rituximab) infusion depends on your medical condition and how your body responds to the medication. Make sure you know when your infusions are scheduled and mark the dates on your calendar so you don’t miss a treatment. There are also several apps for your phone that can help you keep track.
Each Ruxience (rituximab) infusion appointment can last almost the full day because of the time it takes to receive premedications and Ruxience (rituximab) infusion. Please plan accordingly for this time. Make sure you dress comfortably, bring water and food, and have something to help you pass the time, such as a book or music.
Your oncologist will give you premedications, such as steroids, acetaminophen (Tylenol), and antihistamines, before each Ruxience (rituximab) infusion. These medications can help lower the risk of an infusion-related reaction, which can be very serious.
Check your temperature regularly, such as once a day, when you’re receiving Ruxience (rituximab) treatment. Call your care team immediately if your temperature is 100.4 degrees Fahrenheit or higher; this means you have a fever. It’s important for your oncologist to know if you get sick, and sometimes a fever might be the only sign that you’re sick.
If you experience nausea and vomiting while receiving Ruxience (rituximab), contact your oncologist. There are several antiemetic medications, such as ondansetron (Zofran) or promethazine (Phenergan), your oncologist might prescribe to help manage it.
We don’t know if Ruxience (rituximab) passes into human milk. But, because of the risks to a nursing infant, you shouldn’t breastfeed while taking Ruxience (rituximab) and for 6 months after the last dose.
Ruxience (rituximab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
People taking rituximab products might experience infusion-related reactions. These reactions are most common within the first two hours of the first infusion. Symptoms include rash and red skin, swelling, trouble breathing, chest pain, irregular heartbeat, and low blood pressure. Sometimes, these reactions can be very serious and cause throat swelling, anaphylaxis, or heart attacks. This can be life threatening.
You’ll take several medications before each treatment, such as acetaminophen (Tylenol) and diphenhydramine (Benadryl) to help prevent a reaction. Your nurse will watch you closely during your first treatment, but you should tell them right away if you experience any symptoms during your treatment. If you have a severe reaction to Ruxience (rituximab), you might not be able to continue taking the medication.
Some people receiving rituximab products have experienced serious and sometimes life-threatening skin problems, such as Stevens-Johnson syndrome (SJS), paraneoplastic pemphigus, toxic epidermal necrolysis (TEN), and others. Tell your provider right away if you develop painful blisters, skin wounds, peeling skin, or fever as these are signs of a serious skin reaction that need immediate medical attention.
Risk factors: History of hepatitis B viral infection
Some people who had hepatitis B in the past experienced a new infection (hepatitis B reactivation) after starting medications like rituximab. Your oncologist will test you for hepatitis B virus before you start taking Ruxience (rituximab). If you test positive, you might need treatment for hepatitis B before you start taking Ruxience (rituximab). If you develop a hepatitis B infection during treatment, you’ll need to stop taking Ruxience (rituximab) while your oncologist treats it. Let your oncologist know right away if you experience symptoms of an active hepatitis B infection, such as fever, tiredness, or yellowing of the skin.
Risk factors: Taking Ruxience (rituximab) with chemotherapy | Taking Ruxience (rituximab) for stem cell transplant
Rarely, people taking Ruxience (rituximab) have developed a serious brain condition called progressive multifocal leukoencephalopathy (PML). PML is caused by a virus called JC virus and can lead to brain damage. Let your oncologist know if you’ve PML symptoms while taking Ruxience (rituximab), such as weakness, clumsiness, difficulty speaking, and difficulty walking.
Risk factors: People taking Ruxience (rituximab) for lymphoma
Some people taking medications like Ruxience (rituximab) to treat cancer developed a complication called tumor lysis syndrome (TLS) that can cause damage in multiple areas of the body. TLS happens when cancer cells are destroyed and release what’s inside them, such as potassium and uric acid, into your blood. TLS is most common during the first treatment cycle, and symptoms can appear within 24 hours of the Ruxience (rituximab) infusion. Your oncologist will closely monitor you with lab tests, and might give you extra fluids or a medication such as allopurinol (Zyloprim) to prevent TLS. Let your oncology care team know if you experience symptoms of TLS, such as nausea, tiredness, and no appetite.
Risk factors: Taking Ruxience (rituximab) with chemotherapy
People who take rituximab products like Ruxience (rituximab) can develop serious infections, including viral, bacterial, and fungal infections. If you do get sick, you might need to pause taking Ruxience (rituximab) and start taking other medications to treat the infection. If you develop a serious infection you might have to stop taking Ruxience (rituximab) altogether. Contact your oncologist if you develop signs and symptoms of an infection such as fever, chills, muscle aches, or severe tiredness or weakness.
Serious heart problems have happened during treatment with medications like Ruxience (rituximab). These include heart rhythm changes and heart attacks. If your heart rhythm changes during your treatment, your oncologist might recommend closer monitoring with a test called an electrocardiogram (EKG) during your infusions. If you develop serious heart problems during treatment, your oncologist might stop your Ruxience (rituximab) infusion.
Risk factors: Tumor lysis syndrome | Taking cisplatin
Some people taking medications like Ruxience (rituximab) experienced kidney problems. This was more common in people who developed tumor lysis syndrome or who were taking Ruxience (rituximab) together with a chemotherapy medication called cisplatin. Your oncologist will monitor your kidney health with a blood test while you’re taking Ruxience (rituximab). Let your oncologist know if you have trouble making urine, notice swelling in your hands and feet; these might be symptoms of kidney problems.
Some people have reported stomach pain, intestinal blockage, and tears in the lining of the gut after starting medications like Ruxience (rituximab) together with chemotherapy for NHL. For some people, these side effects appeared 2 months after the start of treatment. Contact your oncologist right away if you have sudden and severe stomach pain, fever, chills, and nausea or vomiting that won’t go away.
Make sure you’re up-to-date with your vaccines before starting Ruxience (rituximab). We don’t know if it’s safe to take live virus vaccines while taking Ruxience (rituximab). You should avoid live vaccines during treatment. And you need to receive any non-live vaccines at least 4 weeks before Ruxience (rituximab) treatment. Talk to your oncologist before getting any vaccine while you’re taking Ruxience (rituximab), even if it’s an inactivated vaccine.
Based on data from human pregnancies, Ruxience (rituximab) can cause harm to an unborn baby. If you’re a female who's able to have babies, you should use effective birth control while taking Ruxience (rituximab) and for 12 months after the last dose. Contact your oncologist right away if you become pregnant while taking Ruxience (rituximab).
Risk factors: People taking Ruxience (rituximab) for autoimmune conditions
We don’t know if it’s safe to take other biologic medications or disease-modifying antirheumatic drugs (DMARDs) together with Ruxience (rituximab). Because taking these medications together might raise your risk for infection, your provider will closely monitor you if they recommend a combination treatment.
Blood cancers
Your oncologist will determine your dose of Ruxience (rituximab) based on your body surface area (BSA) in m². Your oncologist might also give you other anticancer medications along with Ruxience (rituximab).
Non-Hodgkin’s lymphoma
Adults: The typical dose is 375 mg/m² given as an intravenous infusion. How often you’ll receive a dose usually ranges from weekly to every 8 weeks, depending on the type of NHL you have and where you are in the treatment process.
Chronic Lymphocytic Leukemia (CLL)
Adults: The typical dose is to receive one 375 mg/m² intravenous infusion before the start of chemotherapy. Then, your oncologist will raise your dose to 500 mg/m² infused on Day 1 of a 28-day chemotherapy cycle, for up to 6 cycles.
Autoimmune conditions
Your HCP might also give you other medications along with Ruxience (rituximab) to treat your condition.
RA
Adults: The typical starting dose is 1,000 mg infused IV for 2 doses, given 2 weeks apart. The typical maintenance dose is 1,000 mg infused once every 4 to 6 months, depending on your condition.
GPA and MPA
Adults: Your HCP will determine your dose of Ruxience (rituximab) based on your body surface area (BSA) in m². The typical starting dose is 375 mg/m² given as an intravenous infusion weekly for 4 weeks. The typical maintenance dose is 500 mg given as 2 doses 2 weeks apart, then 500 mg every 6 months.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Blood cancers
Certain types of CD20-positive non-Hodgkin’s lymphoma (NHL) in adults
CD20-positive chronic lymphocytic leukemia (CLL) in adults
Autoimmune conditions
Moderate to severe rheumatoid arthritis (RA) in adults
Granulomatosis with polyangitis (GPA) and microscopic polyangitis (MPA) in adults
Rheumatoid arthritis (RA) - adults only
Juvenile idiopathic arthritis (JIA) - people age 2 and older
Psoriatic arthritis (PsA) - adults only
Ankylosing spondylitis (AS) - adults only
Crohn's disease (CD) - people age 6 and older
Ulcerative colitis (UC) - people age 5 and older
Plaque psoriasis - adults only
Hidradenitis suppurativa (HS) - people age 12 and older
Uveitis - people age 2 and older
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Adeyinka, A., et al. (2022). Tumor lysis syndrome. StatPearls.
American Cancer Society. (2024). Fevers.
American Cancer Society. (2024). Infusion or immune reactions.
Bartels, T., et al. (2020). Utilizing a novel four-drug regimen to reduce the incidence of infusion-related reactions for first-dose rituximab infusions: An institutional review of rituximab infusion-related reactions in lymphoma patients. Journal of Clinical Oncology.
Benjamin, O., et al. (2023). Disease-modifying antirheumatic drugs (DMARD). StatPearls.
Fouda, G. E., et al. (2020). Rituximab hypersensitivity: From clinical presentation to management. Frontiers in Pharmacology.
Genentech USA, Inc. (n.d.). What are granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)?
Gupta, A., et al. (2018). Tumor lysis syndrome. Journal of the American Medical Association Oncology.
Hafner, J., et al. (2023). Intestinal perforation. StatPearls.
Hanif, N., et al. (2024). Rituximab. StatPearls.
Kappius, R. H., et al. (2023). Paraneoplastic pemphigus. StatPearls.
National Comprehensive Cancer Network. (2021). Anemia and neutropenia: Low red and white blood cell counts.
National Institute of Neurological Disorders and Stroke. (2024). Progressive multifocal leukoencephalopathy.
Pavlasova, G., et al. (2020). The regulation and function of CD20: An "enigma" of B-cell biology and targeted therapy. Haematologica.
Pfizer Laboratories Div Pfizer Inc. (2024). Ruxience- rituximab-pvvr injection, solution [package insert]. DailyMed.
Saribas, A. S., et al. (2010). JC virus-induced progressive multifocal leukoencephalopathy. Future Virology.
Smith, D. A., et al.(2023). Bowel obstruction. StatPearls.
U.S. Food and Drug Administration. (2023). Biosimilars.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.